Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Avalo Therapeutics Q1 2025 EPS $(1.25) Beats $(1.39) Estimate, Cash On Hand Of Approximately $125 As Of March 31, 2025 Expected To Provide Runway Into 2027, With Optionality To Extend Into 2028

Author: Benzinga Newsdesk | May 12, 2025 07:11am

Posted In: AVTX